Invited commentary  by Bosiers, Marc
Dr Cao. We tended to exclude symptomatic patients above 80
years of age. That is why we had to use age as a continuous variable;
otherwise, we couldn’t have any results.
Dr Jean Becquemin (Creteil, France). It cannot be denied
that the learning curve is very important in this topic of carotid
stenting.
Previous discussants of your paper and yourself have quoted
the French randomized study EVA-3S, comparing CEA and CAS
in symptomatic patients. The final data have not been published
yet, so I am not allowed to give the raw figures. But being a
member of the organizing committee of the study, I can tell you
that most of the complications in the CAS group did not happen in
low-volume centers, but they happened in the group of practitio-
ners who had the high-volume cases. So the problem of learning
curve is important, but it’s not all. Since in the second part of your
study you enlarged the indications to asymptomatic patients, the
improved results may reflect the fact that you have treated less
severe and, thus, less dangerous lesions.
Dr Cao. I have no reply. I agree with you.
INVITED COMMENTARY
Marc Bosiers, MD, Dendermonde, Belgium
After reviewing their 627 carotid angioplasty and stenting
(CAS) procedures performed over the last 6 years, the vascular
team from Perugia, directed by a vascular surgeon, determined that
the caseload necessary to be able to perform CAS with similar
outcomes as carotid endarterectomy (CEA) was 195 cases. Al-
though this figure seems high, I agree that the minimum number
of performed procedures, which ranges from 10 to 30, to be
allowed to perform CAS independently that is currently recom-
mended by different societies, hospitals, and study recruiters is far
too low. In our center we found that we needed approximately 75
cases to lower our complication rate to an ethically acceptable level.
Once this level of expertise was achieved, we observed a similar
switch from CEA to CAS, which was mainly driven by the patient
demands for a minimally invasive procedure with a similar outcome
as surgery.1
Interestingly in the Perugia series, just as in other high-volume
centers, the same shift of the timing of complications from intra-
procedural to postprocedural was observed.2 During CEA, the
emboligenic plaque is removed, but in CAS the plaque material is
compressed into the vessel wall and contained by the stent, which
remains the only protection against embolization after the proce-
dure. As our group has recently found,3 a significant correlation
exists between more postprocedural events and a larger free cell
area of the stent, especially in symptomatic patients.
In this light, one can argue that the recently published data
from the randomized Endarterectomy Versus Angioplasty in Pa-
tients With Severe Symptomatic Carotid Stenosis (EVA-3S) and
Stent Protected Percutaneous Angioplasty of the Carotid vs. End-
arterectomy (SPACE) trials that failed to demonstrate equivalency
for CAS vs CEA needs an in-depth subanalysis of the learning curve
experience of the centers and types of stent (free cell area) that
potentially caused more adverse events in the CAS group.
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